DK3652606T5 - Universel vaccine baseret på delte tumorneoantigener til forebyggelse og behandling af cancere med mikrosatellitinstabilitet (msi) - Google Patents

Universel vaccine baseret på delte tumorneoantigener til forebyggelse og behandling af cancere med mikrosatellitinstabilitet (msi) Download PDF

Info

Publication number
DK3652606T5
DK3652606T5 DK18742985.7T DK18742985T DK3652606T5 DK 3652606 T5 DK3652606 T5 DK 3652606T5 DK 18742985 T DK18742985 T DK 18742985T DK 3652606 T5 DK3652606 T5 DK 3652606T5
Authority
DK
Denmark
Prior art keywords
msi
cancer
prevention
treatment
microsatellite instability
Prior art date
Application number
DK18742985.7T
Other languages
Danish (da)
English (en)
Other versions
DK3652606T3 (da
Inventor
Alfredo Nicosia
Elisa Scarselli
Guido Leoni
Armin Lahm
Original Assignee
Nouscom Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom Ag filed Critical Nouscom Ag
Application granted granted Critical
Publication of DK3652606T3 publication Critical patent/DK3652606T3/da
Publication of DK3652606T5 publication Critical patent/DK3652606T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10Sequence alignment; Homology search
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18742985.7T 2017-07-12 2018-07-12 Universel vaccine baseret på delte tumorneoantigener til forebyggelse og behandling af cancere med mikrosatellitinstabilitet (msi) DK3652606T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17181026 2017-07-12
PCT/EP2018/069032 WO2019012082A1 (en) 2017-07-12 2018-07-12 UNIVERSAL VACCINE BASED ON SHARED TUMOR NEO-ANTIGENS FOR THE PREVENTION AND TREATMENT OF MICRO-SATELLITE INSTABILITY CANCER (MSI)

Publications (2)

Publication Number Publication Date
DK3652606T3 DK3652606T3 (da) 2023-03-13
DK3652606T5 true DK3652606T5 (da) 2024-08-26

Family

ID=59366234

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18742985.7T DK3652606T5 (da) 2017-07-12 2018-07-12 Universel vaccine baseret på delte tumorneoantigener til forebyggelse og behandling af cancere med mikrosatellitinstabilitet (msi)

Country Status (19)

Country Link
US (1) US11578109B2 (enExample)
EP (1) EP3652606B1 (enExample)
JP (1) JP7274223B2 (enExample)
KR (1) KR102709778B1 (enExample)
CN (1) CN111328420B (enExample)
AU (1) AU2018298849B2 (enExample)
BR (1) BR112020000590A2 (enExample)
CA (1) CA3069047A1 (enExample)
DK (1) DK3652606T5 (enExample)
ES (1) ES2940087T3 (enExample)
FI (1) FI3652606T3 (enExample)
HU (1) HUE061840T2 (enExample)
IL (1) IL271966B2 (enExample)
MX (1) MX2020000413A (enExample)
NZ (1) NZ759940A (enExample)
PL (1) PL3652606T3 (enExample)
PT (1) PT3652606T (enExample)
SG (1) SG11202000250PA (enExample)
WO (1) WO2019012082A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220349010A1 (en) 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
IL280112B2 (en) 2018-07-26 2025-11-01 Curevac Netherlands B V Cancer vaccines for breast cancer
CA3106567A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
IL280113B2 (en) 2018-07-26 2025-11-01 Curevac Netherlands B V Cancer vaccines for uterine cancer
US12005104B2 (en) 2018-07-26 2024-06-11 Curevac Netherlands B.V. Cancer vaccines for colorectal cancer
WO2020022903A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US20220008525A1 (en) * 2019-02-07 2022-01-13 Arizona Board Of Regents On Behalf Of Arizona State University Cancer specific frameshift vaccines
CN114980920A (zh) 2019-11-18 2022-08-30 詹森生物科技公司 基于突变体calr和jak2的疫苗及其用途
US20230212243A1 (en) * 2020-05-12 2023-07-06 Institut Curie Neoantigenic Epitopes Associated with SF3B1 Mutations
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022216856A1 (en) * 2021-04-06 2022-10-13 Board Of Regents, The University Of Texas System Methods and compositions comprising mhc class i peptides

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
AU2003232485A1 (en) * 2002-04-18 2003-10-27 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
WO2004092338A2 (en) * 2003-04-11 2004-10-28 Diadexus, Inc. Compositions, splice variants and methods relating to cancer specific genes and proteins
CN1824325A (zh) * 2005-12-16 2006-08-30 武汉大学 人乳头病毒dna嵌合疫苗及制备方法和应用
EP2687540A1 (en) * 2006-10-17 2014-01-22 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
WO2010136598A1 (en) 2009-05-29 2010-12-02 Morphosys Ag A collection and methods for its use
JP2013523084A (ja) * 2010-04-09 2013-06-17 オンコセラピー・サイエンス株式会社 Cdca5ペプチドおよびそれを含むワクチン
ES2575980T3 (es) * 2011-03-24 2016-07-04 Institut National De La Santé Et De La Recherche Médicale (Inserm) Mutante de HSP110 dominante negativo y su uso en el pronóstico y el tratamiento de cánceres
KR102015648B1 (ko) * 2011-08-12 2019-08-28 온코세라피 사이언스 가부시키가이샤 Mphosph1 펩티드 및 이를 포함한 백신
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクRuprecht−Karls−Universitaet Heidelberg がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp)
KR101810840B1 (ko) * 2012-12-13 2017-12-20 루프레히트-칼스-유니페어지테트 하이델베르크 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp)
US9205140B2 (en) * 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
US20150337388A1 (en) * 2012-12-17 2015-11-26 Virginia Tech Intellectual Properties, Inc. Methods and compositions for identifying global microsatellite instability and for characterizing informative microsatellite loci
WO2015112930A1 (en) * 2014-01-27 2015-07-30 Yale University Novel methods of identifying patients responsive to immunotherapeutic strategies
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
CN106350578A (zh) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Ny-eso-1在微卫星不稳定性肠癌的诊断和治疗中的应用
WO2017020026A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas

Also Published As

Publication number Publication date
EP3652606B1 (en) 2023-01-11
HUE061840T2 (hu) 2023-08-28
PL3652606T3 (pl) 2023-04-24
KR20200029443A (ko) 2020-03-18
CN111328420B (zh) 2023-07-25
IL271966B1 (en) 2024-09-01
ES2940087T3 (es) 2023-05-03
IL271966B2 (en) 2025-01-01
CN111328420A (zh) 2020-06-23
RU2019144505A3 (enExample) 2021-08-12
AU2018298849B2 (en) 2022-07-14
CA3069047A1 (en) 2019-01-17
FI3652606T3 (fi) 2023-03-16
DK3652606T3 (da) 2023-03-13
PT3652606T (pt) 2023-03-16
NZ759940A (en) 2023-07-28
IL271966A (en) 2020-02-27
AU2018298849A1 (en) 2020-01-02
JP7274223B2 (ja) 2023-05-16
SG11202000250PA (en) 2020-02-27
EP3652606A1 (en) 2020-05-20
JP2020532288A (ja) 2020-11-12
RU2019144505A (ru) 2021-08-12
MX2020000413A (es) 2020-09-28
BR112020000590A2 (pt) 2020-07-14
WO2019012082A1 (en) 2019-01-17
US20200222519A1 (en) 2020-07-16
US11578109B2 (en) 2023-02-14
WO2019012082A9 (en) 2019-05-02
KR102709778B1 (ko) 2024-09-26

Similar Documents

Publication Publication Date Title
DK3652606T3 (da) Universel vaccine baseret på delte tumorneoantigener til forebyggelse og behandling af cancere med mikrosatellitinstabilitet (msi)
DK3600281T3 (da) Kombinationsbehandling til behandling eller forebyggelse af tumorer
IL269150A (en) Compositions and methods for treating cancer
IL268814A (en) Compositions and methods for treatment of cancer
IL263224A (en) Methods and compositions for treating cancers
IL258955A (en) Compositions and methods for treatment of cancer
DK4028010T3 (da) Vs-6063 i kombination med ch5126766 til behandlingen af kræft
IL281277A (en) Preparations and methods for treating viral infections
DK4019019T3 (da) Anvendelse af riluzol, riluzolprodrugs eller riluzolanaloger med immunterapier til cancerbehandling
PT3242678T (pt) Preparações combinadas para o tratamento de cancro ou infeção
IL269157A (en) Compositions and methods for treating cancer
HUE053944T2 (hu) 7-Szubsztituált szulfonimidoilpurinon vegyületek vírusfertõzés kezelésére és megelõzésére
IL258741B (en) Combination of bcl-2 inhibitor and mek inhibitor for cancer treatment
IL275550A (en) Recombinant virus on a region reduced from optimal for a codon pair and its use for cancer treatment
HUE060791T2 (hu) Antigén peptidek rák megelõzésére és kezelésére
IL258259A (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
IL280145A (en) Methods and compositions using recombinant dendritic cells for cancer therapy
EP3802557A4 (en) THERAPEUTIC TREATMENT OF MICROSATELLITE-UNSTABLE CANCER
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
HUE050863T2 (hu) Rák és cukorbetegség kezelésére alkalmazható 6-aril-4-(morfolin-4-il)-1H-piridin-2-on vegyületek
HUE045906T2 (hu) Új szulfonimidoilpurinon vegyületek és származékok vírusfertõzés kezelésére és megelõzésére
LT3496743T (lt) Kompozicijos ir metodai, skirti vėžio gydymui arginino deplecija ir imunoonkologiniais preparatais
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3759083T3 (da) 2,4-diaminoquinazolinderivater og anvendelse deraf til behandling af virusinfektioner, cancer eller allergier
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer